SPRIG Equity

SPRIG Equity is a growth equity and late-stage venture capital firm committed to enhancing patient outcomes by partnering with leading teams and advanced medical technologies. The firm focuses on investments in medical devices, diagnostics, and tech-enabled services that have the potential to revolutionize healthcare.

Established in 2022, SPRIG Equity has demonstrated strong momentum with four portfolio investments to date: SetPoint Medical, Conformal Medical, Pi-Cardia, and Cytovale. These companies are at the forefront of developing innovative solutions in their respective fields, aligning with SPRIG Equity's mission to advance patient care through transformative medical technologies.

The firm's leadership includes Managing Partner Evan Norton, who co-founded SPRIG Equity after nearly a decade leading Abbott's corporate venture group. The team also comprises Rebecca Raabe, an experienced MedTech investor and operator, and Katie Arnold, CEO and founder of SPRIG Consulting, a leading medical technology strategy and commercialization consulting firm. This partnership allows SPRIG Equity to leverage proprietary deal flow and an excellent track record to partner with companies best positioned to solve unmet needs.

SPRIG Equity's inaugural fund, SPRIG Equity Fund I, closed in April 2025 with $50 million in assets under management. This achievement reflects the strength of the firm's investment strategy, proprietary deal sourcing, and the team's expertise in identifying and building great companies that can transform patient care while delivering exceptional returns.

The firm's offices are located in the Chicago area and Orange County, California, enabling them to actively invest in late-stage opportunities across the medical technology sector. SPRIG Equity's approach combines agility, insights, and expertise to provide more than just capital to its investments, aiming to solidify the future of healthcare through strategic partnerships and investments in medical innovations.